Low-dose aspirin may be beneficial for women who are at high risk of developing preterm preeclampsia, according to results of a multicenter, double-blind trial published in The New England Journal of Medicine.
Researchers randomly assigned 1776 women with singleton pregnancies who were at high risk of preterm preeclampsia to receive either a daily dose of 150 mg of aspirin or a placebo from 11 to 14 weeks of gestation until 36 weeks of gestation. The study’s primary outcome was delivery with preeclampsia before reaching 37 weeks of gestation. During the trial, 152 women withdrew their consent and 4 women were lost during the study’s follow-up, leaving 822 women in the placebo group and 798 women in the aspirin group.
Preterm preeclampsia occurred in 13 women from the aspirin group and 35 in the placebo group (odds ratio in the aspirin group, 0.38; 95% confidence interval, 0.20 to 0.74; P = 0.004). Adherence was found to be good with reported intake of over 85% or more of the required tablets in 79.9% of the participants. No significant difference was seen between the groups in the incidence of neonatal adverse outcomes or other adverse outcomes.
The researchers concluded that treating women at high risk for preterm preeclampsia with low-dose aspirin resulted in lower rates of diagnosis of the condition.